References
- Ledger TS. Streptococcus pyogenes primary peritonitis. Case Rep. 2018;2018:bcr-2017-223890.
- Westwood DA, Roberts RH. Management of primary group a streptococcal peritonitis: a systematic review. Surg Infect. 2013;14(2):171–176.
- Tilanus AMR, de Geus HRH, Rijnders BJA, et al. Severe group a streptococcal toxic shock syndrome presenting as primary peritonitis: a case report and brief review of the literature. Int J Infect Dis. 2010;14(Suppl 3):e208–e212.
- Moskovitz M, Ehrenberg E, Grieco R, et al. Primary peritonitis due to group A streptococcus. J Clin Gastroenterol. 2000;30(3):332–335.
- Sakuraba S, Ueda S, Tokuda S, et al. Group a streptococcal toxic Shock-Like syndrome in a male presenting as primary peritonitis: a case report and a review in Japan. Case Rep Gastrointestinal Med. 2019;8:1–5.
- Malota M, Felbinger TW, Ruppert R, et al. Group A streptococci: a rare and often misdiagnosed cause of spontaneous bacterial peritonitis in adults. Int J Surg Case Rep. 2015;6:251–255.
- Monneuse O, Tissot E, Gruner L, et al. Diagnosis and treatment of spontaneous group a streptococcal peritonitis. Br J Surg. 2010;97(1):104–108.
- Mehta S, McGeer A, Low DE, et al. Morbidity and mortality of patients with invasive group a streptococcal infections admitted to the ICU. Chest. 2006;130(6):1679–1686.
- Wahab A, Nasir B. Streptococcal toxic shock syndrome with primary group A streptococcus peritonitis in a healthy female. J Community Hosp Intern Med Perspect. 2018;8(5):317–320.
- Howell MD, Davis AM. Management of sepsis and septic Shock. JAMA. 2017;317(8):847–848.
- Solomkin JS. Evaluating evidence and grading recommendations: the SIS/IDSA guidelines for the treatment of complicated intra-abdominal infections. Surg Infect. 2010;11(3):269–274.
- Andreoni F, Zürcher C, Tarnutzer A, et al. Clindamycin affects group A streptococcus virulence factors and improves clinical outcome. J Infect Dis. 2017;215(2):269–277.
- Babiker A, Li X, Lai YL, et al. Effectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study. Lancet Infect Dis. 2021;21(5):697-710
- Patterson MJ. Streptococcus. In: Baron S, ed. Medical microbiology. 4th ed. University of Texas Medical Branch at Galveston; 1996. Chapter 13.
- Madsen MB, Hjortrup PB, Hansen MB, et al. Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial. Intensive Care Med. 2017;43(11):1585–1593.
- Kadri SS, Swihart BJ, Bonne SL, et al. Impact of intravenous immunoglobulin on survival in necrotizing fasciitis with vasopressor-dependent shock: a propensity score-matched analysis from 130 US hospitals. Clin Infect Dis. 2017;64(7):877–885.
- Darenberg J, Ihendyane N, Sjölin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37(3):333–340.
- Carapetis JR, Jacoby P, Carville K, et al. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis. 2014;59(3):358–365.